A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung

Trial Profile

A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs PEN 221 (Primary)
  • Indications Gastrointestinal cancer; Lung cancer; Merkel cell carcinoma; Neuroendocrine tumours; Paraganglioma; Pheochromocytoma; Small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Tarveda Therapeutics
  • Most Recent Events

    • 04 Jan 2017 According to a Tarveda Therapeutics media release, patients are being treated in this trial.
    • 22 Nov 2016 Status changed from not yet recruiting to recruiting.
    • 29 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top